A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Brain cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Biomarker; Pharmacodynamics
- Acronyms IPINIVO
- Sponsors Agenus
- 02 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Aug 2017 Status changed from not yet recruiting to recruiting.
- 22 Jul 2017 New trial record